The importance of true collaboration in efforts to increase diversity in genetic analyses
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In Michael Gross's recent article ('Mind the genome diversity gap'), he rightly states that global health equity demands an overhaul of the current approach to genetic analysis of psychiatric conditions, which relies heavily on European sample collections. Unfortunately, the article missed the mark in its description of work undertaken by the Broad Institute of MIT and Harvard, the Harvard T.H. The two NeuroGAP research arms are built around a core principle of collaboration and the recognition that biological samples collected in any country represent resources that belong to (and therefore must be controlled by) the people who live there. It is incorrect to state that we are removing all samples from the continent; both NeuroGAP-Psychosis and NeuroDev are storing samples in biorepositories affi liated with the institution where they were collected. Furthermore, NeuroGAP-Psychosis is conducting all DNA extraction in-country. One aliquot from each participant will be sent to the Broad Institute for genotyping and sequencing to reduce batch effects. At least one aliquot from each participant will be banked on-site, where it will be governed by the rules of its institution. All analyses will be done in collaboration between the PIs from Broad/Harvard and the African institutions.
GINGER (https://ginger.sph.harvard. edu/) is being implemented in the context of the research projects to build a strong neuropsychiatric genetics research community in Africa and to develop the scientifi c infrastructure and capacity to support future work. Students, trainees, and investigators who participate in GINGER are trained under a curriculum developed jointly by Broad, the Harvard T.H. Chan School, and the African institutions. The trainings are taught together with local faculty to ensure that the expertise remains in the collaborating nations. In July 2017, GINGER fellows spent two weeks at Broad and in July 2018 they will spend two weeks in the UK as part of their training.
Based at the University of Oxford, NeuroGenE (https://neurogene.com/) is a program of ethics grounded in the recognition that, while psychiatric genomics has the potential to transform how mental disorders are diagnosed and treated in the global context, the research can raise complex ethical dilemmas including risk of misinterpretation. Guided by its Africa Ethics Working Group (which is cochaired by scientists from Ethiopia and Kenya and includes members from South Africa and Uganda), NeuroGenE is undertaking collaborative research that will generate ethically grounded strategies to inform research and public policy applications of psychiatric genomics.
Beyond Africa, Stanley Global's Asia Initiative has launched three collaborative studies with goals similar to those of NeuroGAP in Africa. In China, the Stanley Center has partnered with researchers at Shanghai Jiao Tong University in Shanghai and The First Affi liated Hospital of Xi'an Jiaotong University in Xi'an to study the genetics of schizophrenia. In Japan, we collaborate with the Tokyo Metropolitan Institute of Medical Sciences to study the genetics of schizophrenia and bipolar disorder. Stanley Global and the three collaborating institutions in China and Japan will co-host a Pan-Asia symposium in Shanghai in July 2018 with the aim of building relationships, fostering deeper collaborations, and building global capacity.
Mental illness knows no borders, yet our limited understanding of the biology of neuropsychiatric disease is based almost exclusively on people of European descent. Changing this inequitable pattern by building true partnerships with colleagues and citizens in every country and in every culture is long overdue.
Only by engaging local scientists and physicians to collaboratively understand all populations will we identify the novel biomarkers, diagnostics, and ultimately therapeutics that will benefi t everyone. Success must not only be measured in the volume of data we collect, but also by the number of long-lasting scientifi c partnerships we can build across the world and by the number of people in every country who choose to work together in this shared process of discovery.
To understand mental illness, diversity is biologically necessary and, as noted by Michael Gross, a point in which we are in absolute agreement, essential for the pursuit of global mental health equity.
